06/2005 Press Release

BioAlliance Pharma Strengthens Global Management Team With Appointment of New CFO

Piers Morgan brings international financial experience gained in the UK as BioAlliance completes private placement and prepares to file for EU registration and initiate a pivotal Phase III trial of miconazole Lauriad ® in the US

PARIS - June 6, 2005 - BioAlliance Pharma, a biopharmaceutical company focused on the field of drug resistance, announced today the appointment of Piers Morgan as Chief Financial Officer.

Morgan, 38, will play a key role in the substantial private placement currently under way as the company prepares to file for EU registration and to embark on a pivotal Phase III trial of its lead product, miconazole Lauriad® for treatment of oropharyngeal candidiasis in immune compromised patients. He comes to BioAlliance Pharma after more than four years as finance director of Arrow Therapeutics, a small molecule anti-infective research and development company based in London. His responsibilities at Arrow included raising EUR43.6 million ($54.7 million) in new equity investment and arranging a further EUR14.5 million ($18.2 million) in debt, tax rebates and government grants.

Prior to joining Arrow, Morgan spent nine years in investment banking. From 1997-2000, he worked at Ernst & Young on a wide range of global M&A transactions, including fund-raisings, privatizations, acquisitions, disposals and take-overs. He was also the founder-director of Ernst & Young's London-based Life Sciences M&A practice. From 1992 - 1997 he worked at Close Brothers Corporate Finance, a UK-listed investment bank, on the capital markets and M&A teams, and overall has advised on some 80 completed transactions in a range of sectors. Prior to investment banking, he worked for the London office of PriceWaterhouseCoopers from 1988-1992, where he qualified as a Chartered Accountant, working in the Management Consulting and Audit practices. Piers Morgan holds a degree in Law and Management Studies from Cambridge University.

"The appointment of Piers Morgan further reinforces the international management team at BioAlliance Pharma," said Dominique Costantini, M.D., president and CEO of BioAlliance Pharma. "We are seeking global success and therefore believe it essential to take a global approach in building our management. We expect Piers’ experience in international life science finance to be a significant asset in the continuing successful growth of our company."

About BioAlliance Pharma
BioAlliance Pharma is a privately held late stage biopharmaceutical company focused on drug resistance through development and commercialization of innovative therapeutics targeting markets in cancer, HIV, severe infections and supportive care. The company has two broad proprietary drug delivery systems represented by the Lauriad® adhesive technology and the Transdrug® nanoparticle technology that provide multiple product opportunities. Together with a New Chemical Entities program focused on development of new drugs in oncology and HIV, the company is able to address worldwide markets in the EU, US, and Asia.

The company’s lead product within its adhesive technology program, the miconazole Lauriad® 50 mg Bioadhesive Buccal Tablet, is being investigated in two recently completed Phase III trials in Europe for treatment of oropharyngeal candidiasis in cancer and HIV patients. EU registration is on track for filing by the end of Q2 2005 and a pivotal Phase III trial in the same indication is planned to start in the U.S. later this year. A near term follow-on product, acyclovir Lauriad® for treatment of oral herpes, using the same delivery system, entered a Phase I clinical trial in April in the EU. A Phase I/II trial in hepatocellular carcinoma utilizing the company’s doxorubicin Transdrug® nanoparticle delivery technology is ongoing in Europe, and has been granted orphan drug status by the EMEA and the US FDA.

For additional company background, click here.

Company Contact

Richard Keatinge
Vice President, Business Development
BioAlliance Pharma SA
Tel : +33 (0) 1 45 58 76 00
richard.keatinge@bioalliancepharma.com

Media Contact
Andrew Lloyd & Associates
Andrew Lloyd
Tel : +44 1 273 675100
Gilles Petitot
Tel : +33 1 56 54 07 00